by • March 22, 2016 • No Comments
SALT LAKE CITY, UT–(Marketwired – Mar 23, 2016) – Amedica Corporation (NASDAQ: AMDA), a company which develops and commercializes silicon nitride ceramics as a biomaterial platform, is cheerful to announce its initially fabrication of harsh, three-dimensional structures by a 3D printing system called robotic deposition, or robocasting. The final products have been examined under scanning electron microscopy to confirm the integrity and validity of the 3D printing method, and have been shown to complete much like theoretical density and microstructure attributes to the traditionally manufactured silicon nitride fusion devices already in use.
“This innovation speaks to the one-of-a-kind art and science related to our making strength,” said Dr. Sonny Bal, Chairman and Chief Executive Officer. “3D printing of a harsh ceramic material opens next doors, especially in terms of cost advantages, and addressing a variety of OEM partner needs. Custom additive making is a modern innovation, and we are proud to lead the way in 3D printing of our silicon nitride formulation, with its advantages in bone fusion, antibacterial behavior, and unsurpassed strength.”
Robocasting is a freeform fabrication technique for dense ceramics and composites which is based on layered deposition of highly colloidal slurries. The system is fundamentally binder-less and a device can be completely sintered in less than 24 hours. With this innovation, Amedica can now progress in the direction of commercializing 3D printed silicon nitride implants, with controllable porosity levels to address specific clinical needs. This one-of-a-kind making method is promising for the production of anatomically relevant shaped silicon nitride implants, while in addition enabling custom fabrication of bone scaffolds suited for cellular differentiation and neovascularization.
About Amedica Corporation
Amedica is focused on the development and application of interbody implants manufactured with medical-grade silicon nitride ceramic. Amedica markets spinal fusion products and is developing a new generation of wear- and corrosion-resistant implant components for hip and knee arthroplasty as well as dental applications. The Company’s products are manufactured in its ISO 13485 certified making facility and through its partnership with Kyocera, one of the world’s biggest ceramic manufacturers. Amedica’s spine products are FDA-cleared, CE-marked, and are already marketed in the U.S. and prefer markets in Europe and South America through its distributor network and its expanding OEM and private label partnerships.
For additional information on Amedica or its silicon nitride material platform, please visit www.amedica.com.
This press release contains statements which constitute forward-looking statements inside the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include, but are not limited to, the intent, understanding or current expectations of Amedica and participants of its management team with respect to Amedica’s next performance, business operations and acceptance of its innovation platform. Statements relating to Amedica’s expectation which scientific outcomes may outcome in new solutions, increased market opportunities, growth, next products, market acceptance of its products, sales and financial outcomes and much like statements are subject to risks and uncertainties such as the timing and good results of new product introductions, physician acceptance, endorsement, and use of Amedica’s products, regulatory matters, competitor activities, changes in and adoption of reimbursement rates, future product recalls, influences of global economic conditions and changes in foreign currency exchange rates. Additional facts which may cause actual outcomes to differ materially of those contemplated inside this press release can in addition be discovered in Amedica’s Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 24, 2015, and in Amedica’s other filings with the SEC. Amedica disclaims any obligation to update any forward-looking statements.
by admin • March 5, 2017
by admin • November 28, 2016
by admin • November 28, 2016